After FDA setback, MEI, Kyowa confirm phase 2 efficacy with Japanese blood cancer data drop

Kyowa Kirin and MEI Pharma have posted more midphase data on their oncology candidate zandelisib, confirming the efficacy seen in an earlier trial of the PI3K delta inhibitor. But with the FDA raising the bar for the asset, the companies need an ongoing phase 3 to deliver to get the prospect to the U.S. market.